A novel drug to treat Alzheimer’s disorder has effectively passed the first phase of clinical trials. It will be now tested on patients through Priavoid during Phase two clinical trials.
The improvisation in memory and other symptoms were already observed during preclinical studies. The mutant human gene was inserted into older mice to develop Alzheimer’s-like disorder.
PRI-002 was developed by the researchers at Heinrich Heine University and Forschungszentrum Julich. It is known to eliminate toxic beta-amyloid oligomers which are self-replicating proteins.
Alzheimer’s disorder destructs the ability of an individual to memorize, and think. It has been agreed by scientists recently that beta-amyloid oligomers clumps are the major cause of Alzheimer’s disorder.
Nerve cells get disrupted through beta-amyloid oligomers leading to the stopping of their effective functioning. Replication and traveling throughout brain is easy for beta-amyloid oligomers. These oligomers get dissemble into nontoxic monomers through PRI-002. Therefore, it can directly target oligomers without the involvement of the immune system.
Daily dose of PRI-002 was taken by healthy volunteers for 4 weeks during phase I clinical trials and it is shown to be safe for human use.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like